Gut Microbiome: Everyone wins
Microbes can be found in almost every environment – including other organisms. Some cause disease, but many of them live with their hosts in a mutually beneficial relationship, a type of symbiosis called mutualism (McFall-Ngai et al., 2013). These microbial communities are in constant communication with the organisms hosting them, and gut bacteria in particular are known to influence the development, metabolism, immune system and behavior of their hosts (Fraune and Bosch, 2010; Kohl and Carey, 2016).
To peacefully cohabit with each other, the immune system of the host needs to control the number of bacteria without resorting to levels of inflammation that would harm either the bacteria or the host. As in many other areas of research, model organisms are widely used to dissect the molecular mechanisms that orchestrate such complex interactions. For example, the zebrafish – often used for studying development – is a powerful model that can be used to investigate such associations at the tissue, cell and molecular levels.
Most research to date has focused on how the host benefits from symbiosis, and the question of how the microbes benefit has been largely overlooked. Now, in eLife, Karen Guillemin and colleagues at the University of Oregon and the Canadian Institute for Advanced Research – including Annah Rolig as first author – report new details about the relationship between zebrafish larvae and one of their gut symbionts, Aeromonas veronii (Rolig et al., 2018).
Aeromonas are the only group of bacteria that are present throughout the zebrafish life cycle, and they play important roles in immune defense, gut cell growth and the development of the pancreas (Stephens et al., 2015; Burns and Guillemin, 2017). Rolig et al. used a specific strain of A. veronii (Hm21) to study the interactions between the bacteria and immune cells called neutrophils, which are the first immune cells to respond to inflammation and travel to the infected area (Brugman, 2016).
The fish were raised in sterile environments and were devoid of any microbes. Then, single bacteria were added and the interactions with the immune system were analyzed. This revealed that the bacteria produce a molecule that dampens the immune response of the neutrophils and so reduces inflammation.
The sequence of the molecule, which they named AimA (short for Aeromonas immune modulator A), did not resemble any known molecule, but its 3D crystal structure was similar to a molecule secreted by human neutrophils known as Lipocalin-2. Indeed, in experiments mimicking injuries to the zebrafish gut, the protective effect of AimA against inflammation was compromised when mouse Lipocalin-2 was added to the mix. This suggests that both molecules compete for the same receptors on the immune cells because they have similar structures.
Next, Rolig et al. investigated how AimA affected the ‘fitness’ of the Aeromonas and the zebrafish. The researchers created bacteria that lacked AimA and its close paralog AimB, and evaluated their ability to colonize larval zebrafish. Without AimA and AimB, the bacteria were unable to colonize the gut and the number of neutrophils increased, which in turn lead to more inflammation in the gut. However, when purified AimA was added, the mutant bacteria were able to accumulate in the gut and the number of neutrophils went back to normal.
This suggests that AimA mediates the interactions between zebrafish and the Aeromonas bacteria for the benefit of both partners, illustrating a prototypical example of mutualism. AimA is a colonization factor that intervenes early in the establishment of the bacteria in the gut, suppressing the immune response and inflammation in the gut to ensure the survival of the bacteria and the host. By doing so, it potentially allows bacteria to produce different molecules, which may benefit the host in other ways.
Symbiotic relationships have largely been described with a host-centric view, hence many molecular mechanisms may have been overlooked. Rolig et al. add AimA to the sparse list of known mutualistic factors, such as a specific polysaccharide that allows the bacterium Bacteroides fragilis to colonize the gut by activating tolerance in specific immune cells (Round et al., 2011). The anti-inflammatory potential of AimA and its atomic structure pave the way for researchers to test its potential as a therapeutic agent. The study of Rolig et al. highlights the importance of unbiased basic research in the host-microbe field using simple animal models.
References
-
The zebrafish as a model to study intestinal inflammationDevelopmental & Comparative Immunology 64:82–92.https://doi.org/10.1016/j.dci.2016.02.020
-
The scales of the zebrafish: host-microbiota interactions from proteins to populationsCurrent Opinion in Microbiology 38:137–141.https://doi.org/10.1016/j.mib.2017.05.011
-
A place for host-microbe symbiosis in the comparative physiologist's toolboxJournal of Experimental Biology 219:3496–3504.https://doi.org/10.1242/jeb.136325
Article and author information
Author details
Publication history
- Version of Record published: November 6, 2018 (version 1)
Copyright
© 2018, Matos et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,760
- Page views
-
- 135
- Downloads
-
- 1
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
- Immunology and Inflammation
Tristetraprolin (TTP) is a critical negative immune regulator. It binds AU-rich elements in the untranslated-regions of many mRNAs encoding pro-inflammatory mediators, thereby accelerating their decay. A key but poorly understood mechanism of TTP regulation is its timely proteolytic removal: TTP is degraded by the proteasome through yet unidentified phosphorylation-controlled drivers. In this study, we set out to identify factors controlling TTP stability. Cellular assays showed that TTP is strongly lysine-ubiquitinated, which is required for its turnover. A genetic screen identified the ubiquitin E3 ligase HUWE1 as a strong regulator of TTP proteasomal degradation, which we found to control TTP stability indirectly by regulating its phosphorylation. Pharmacological assessment of multiple kinases revealed that HUWE1-regulated TTP phosphorylation and stability was independent of the previously characterized effects of MAPK-mediated S52/S178 phosphorylation. HUWE1 function was dependent on phosphatase and E3 ligase binding sites identified in the TTP C-terminus. Our findings indicate that while phosphorylation of S52/S178 is critical for TTP stabilization at earlier times after pro-inflammatory stimulation, phosphorylation of the TTP C-terminus controls its stability at later stages.
-
- Immunology and Inflammation
A genetic variant in the gene PTPN22 (R620W, rs2476601) is strongly associated with increased risk for multiple autoimmune diseases and linked to altered TCR regulation and T cell activation. Here, we utilize Crispr/Cas9 gene editing with donor DNA repair templates in human cord blood-derived, naive T cells to generate PTPN22 risk edited (620W), non-risk edited (620R) or knock out T cells from the same donor. PTPN22 risk edited cells exhibited increased activation marker expression following non-specific TCR engagement, findings that mimicked PTPN22 KO cells. Next, using lentiviral delivery of T1D patient-derived TCRs against the pancreatic autoantigen, islet-specific glucose-6 phosphatase catalytic subunit-related protein (IGRP), we demonstrate that loss of PTPN22 function led to enhanced signaling in T cells expressing a lower avidity self-reactive TCR, but not a high avidity TCR. In this setting, loss of PTPN22 mediated enhanced proliferation and Th1 skewing. Importantly, expression of the risk variant in association with a lower avidity TCR also increased proliferation relative to PTPN22 non-risk T cells. Together, these findings suggest that, in primary human T cells, PTPN22 rs2476601 contributes to autoimmunity risk by permitting increased TCR signaling and activation in mildly self-reactive T cells, thereby potentially expanding the self-reactive T cell pool and skewing this population toward an inflammatory phenotype.